NCT06400251 2026-04-13Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)National Cancer Institute (NCI)Phase 2 Active not recruiting35 enrolled 10 charts